Labelling molecules with carbon-14 allows them to be detected in situ, providing an essential tool for determining the behaviour and fate of chemical compounds in organisms and in the environment.
Contract research organisations (CROs) are playing an ever increasing role in supporting drug development programmes as large pharmaceutical companies and biotechs often look to outsource their non-core activities.This article, featured in the latest edition of European Pharmaceutical Contractor magazine, will examine some key CROs offering the synthesis of carbon-14 (14C)-radiolabelled compounds and will provide examples of those organisations performing 14C studies.
View the European Pharmaceutical Contractor Magazine website